Samuel C. Blackman - 05 Jan 2024 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Reporting relationship: Head of Research and Developme
Issuer ticker: DAWN
Reported as of: 05 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2024, 19:22:06 UTC
Prior SEC filing: 17 Nov 2023
Next SEC filing: 20 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Charles N. York II, as Attorney-in-Fact

Key filing fact

Samuel C. Blackman filed Form 4 for Day One Biopharmaceuticals, Inc. (DAWN) on 09 Jan 2024.

Key facts

This page summarizes Samuel C. Blackman's Form 4 filing for Day One Biopharmaceuticals, Inc. (DAWN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 Jan 2024, 19:22.

Change

Previous filing in this sequence was filed on 17 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Award

Transaction value: $0
Shares: +148,000
Change %
Price: $0.000000
Shares after: 148,000
Date: 05 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 148,000
Exercise price: $14.44
Footnotes: F1

DAWN transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +97,000
Change %
Price: $0.000000
Shares after: 97,000
Date: 05 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 97,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F3

The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.